GLP1_NEW
ECC5004 10 mg tablet once daily
ECC500_PO_10MG_QD
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.77 (0.01 to 71.16) | 0.52 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 0.77 (0.06 to 7.11) | 0.75 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 0.36 (0.01 to 11.20) | 0.79 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 0.09 (0.00 to 1.23) | 0.96 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 0.90 (0.14 to 4.77) | 0.65 |